Ryan Lynch has served as Crescent’s treasurer, senior vice president of finance and chief accounting officer since December 2024. Prior to joining Crescent, Mr. Lynch served as vice president of finance at Kelonia Therapeutics, where he was responsible for overseeing the company’s finance and accounting functions. Prior to Kelonia, Mr. Lynch served as senior director, corporate controller at Morphic Therapeutic, a biopharmaceutical company and wholly owned subsidiary of Morphic Holding, a Nasdaq-listed biopharmaceutical company that was acquired by Eli Lilly and Company in 2024, where he was responsible for overseeing the company’s finance and accounting functions. Prior to joining Morphic, Mr. Lynch held positions of increasing responsibility at Concert Pharmaceuticals from 2014 to 2019, most recently serving as senior director, corporate controller. Mr. Lynch received an MS in accounting from the University of Massachusetts Amherst and a BBA in accounting from the University of Massachusetts Amherst. Mr. Lynch is a licensed certified public accountant in Massachusetts.